

RealRate

PHARMACEUTICAL 2022

Terns Pharmaceuticals Inc. Rank 72 of 466









PHARMACEUTICAL 2022



RealRate

Terns Pharmaceuticals Inc. Rank 72 of 466

The relative strengths and weaknesses of Terns Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Terns Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Terns Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 178% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	166,930
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,820
Liabilities, Non-Current	0
Other Assets	94
Other Compr. Net Income	-214
Other Expenses	508
Other Liabilities	947
Other Net Income	210
Other Revenues	1,000
Property and Equipment	1,046
Research and Development	31,311
Selling, General and Administrative Expense	19,549

Output Variable	Value in 1000 USD
Assets	168,070
Liabilities	7,767
Expenses	51,368
Revenues	1,000
Stockholders Equity	160,303
Net Income	-50,158
Comprehensive Net Income	-50,265
Economic Capital Ratio	256%

